Does the ACB scale better predict adverse clinical outcomes compared to other anticholinergic burden scales in older adults?
The ACB scale may be a helpful tool for primary care and geriatrics clinicians to identify older adults at high risk for adverse outcomes due to anticholinergic burden.
Compared with the 2 other scales studied, the ACB shows good dose-response relationships between anticholinergic burden and a variety of adverse outcomes in older adults. For primary care and geriatrics clinicians, the ACB may be a helpful tool for identifying high-risk populations for interventions.
Hsu et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: